Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Carcinoma of Unknown Primary
NCT02590055Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel in carcinoma of unknown primary (CUP), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
gemcitabinedocetaxel
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT02590055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590055.